eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
biomarkers, tumor
drug therapy, combination
immunotherapy
melanoma
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
03
03
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
15
4
2022
Statut:
ppublish
Résumé
Immune checkpoint blockade (ICB) targeting programmed death ligand-1 (PD-L1)/programmed cell death protein-1 (PD-1) pathway has become an attractive strategy for cancer treatment; however, unsatisfactory efficacy has limited its clinical benefits. Therefore, a more comprehensive understanding of the regulation of PD-L1 expression is essential for developing more effective cancer immunotherapy. Recent studies have revealed the important roles of eukaryotic elongation factor 2 kinase (eEF2K) in promoting epithelial-mesenchymal transition (EMT), angiogenesis, tumor cell migration and invasion; nevertheless, the exact role of eEF2K in the regulation of tumor immune microenvironment (TIME) remains largely unknown. In this study, we used a cohort of 38 patients with melanoma who received anti-PD-1 treatment to explore the association between eEF2K expression and immunotherapy efficacy against melanoma. Immunoprecipitation-mass spectrometry analysis and in vitro assays were used to examine the role and molecular mechanism of eEF2K in regulating PD-L1 expression. We also determined the effects of eEF2K on tumor growth and cytotoxicity of CD8 High eEF2K expression is correlated with better therapeutic response and longer survival in patients with melanoma treated with PD-1 monoclonal antibody (mAb). Moreover, eEF2K protein expression is positively correlated with PD-L1 protein expression. Mechanistically, eEF2K directly bound to and inactivated glycogen synthase kinase 3 beta (GSK3β) by phosphorylating it at serine 9 (S9), leading to PD-L1 protein stabilization and upregulation, and subsequently tumor immune evasion. Knockdown of eEF2K decreased PD-L1 expression and enhanced CD8 Our results suggest that eEF2K may serve as a biomarker for predicting therapeutic response and prognosis in patients receiving anti-PD-1 therapy, reveal a vital role of eEF2K in regulating TIME by controlling PD-L1 expression and provide a potential combination therapeutic strategy of eEF2K inhibition with ICB therapy.
Sections du résumé
BACKGROUND
Immune checkpoint blockade (ICB) targeting programmed death ligand-1 (PD-L1)/programmed cell death protein-1 (PD-1) pathway has become an attractive strategy for cancer treatment; however, unsatisfactory efficacy has limited its clinical benefits. Therefore, a more comprehensive understanding of the regulation of PD-L1 expression is essential for developing more effective cancer immunotherapy. Recent studies have revealed the important roles of eukaryotic elongation factor 2 kinase (eEF2K) in promoting epithelial-mesenchymal transition (EMT), angiogenesis, tumor cell migration and invasion; nevertheless, the exact role of eEF2K in the regulation of tumor immune microenvironment (TIME) remains largely unknown.
METHODS
In this study, we used a cohort of 38 patients with melanoma who received anti-PD-1 treatment to explore the association between eEF2K expression and immunotherapy efficacy against melanoma. Immunoprecipitation-mass spectrometry analysis and in vitro assays were used to examine the role and molecular mechanism of eEF2K in regulating PD-L1 expression. We also determined the effects of eEF2K on tumor growth and cytotoxicity of CD8
RESULTS
High eEF2K expression is correlated with better therapeutic response and longer survival in patients with melanoma treated with PD-1 monoclonal antibody (mAb). Moreover, eEF2K protein expression is positively correlated with PD-L1 protein expression. Mechanistically, eEF2K directly bound to and inactivated glycogen synthase kinase 3 beta (GSK3β) by phosphorylating it at serine 9 (S9), leading to PD-L1 protein stabilization and upregulation, and subsequently tumor immune evasion. Knockdown of eEF2K decreased PD-L1 expression and enhanced CD8
CONCLUSIONS
Our results suggest that eEF2K may serve as a biomarker for predicting therapeutic response and prognosis in patients receiving anti-PD-1 therapy, reveal a vital role of eEF2K in regulating TIME by controlling PD-L1 expression and provide a potential combination therapeutic strategy of eEF2K inhibition with ICB therapy.
Identifiants
pubmed: 35347072
pii: jitc-2021-004026
doi: 10.1136/jitc-2021-004026
pmc: PMC8961175
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
B7-H1 Antigen
0
CD274 protein, human
0
Programmed Cell Death 1 Receptor
0
EEF2K protein, human
EC 2.7.1.17
Glycogen Synthase Kinase 3 beta
EC 2.7.11.1
Eef2k protein, mouse
EC 2.7.11.20
Elongation Factor 2 Kinase
EC 2.7.11.20
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Biochem Soc Trans. 2015 Jun;43(3):328-32
pubmed: 26009171
J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86
pubmed: 12615961
Theranostics. 2020 Jan 1;10(4):1833-1848
pubmed: 32042339
Int J Cancer. 2020 Mar 1;146(5):1383-1395
pubmed: 31286509
Cell Death Differ. 2021 Jun;28(6):1773-1789
pubmed: 33328570
Nat Commun. 2020 Apr 3;11(1):1669
pubmed: 32245950
Int J Cancer. 2011 Aug 1;129(3):629-35
pubmed: 20857494
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Oncogene. 2018 Aug;37(34):4639-4661
pubmed: 29765155
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Biochem J. 2020 Nov 27;477(22):4367-4381
pubmed: 33094805
Cancer Res. 2011 Apr 1;71(7):2654-63
pubmed: 21307130
EMBO Mol Med. 2014 Oct 20;6(12):1542-60
pubmed: 25330770
Mol Cell Biol. 2014 Jun;34(12):2294-307
pubmed: 24732796
Autophagy. 2013 Feb 1;9(2):208-19
pubmed: 23182879
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Eur J Biochem. 1980 Jun;107(2):519-27
pubmed: 6249596
Eur J Biochem. 1990 Aug 17;191(3):639-45
pubmed: 2390990
Cell. 2013 May 23;153(5):1064-79
pubmed: 23706743
Cell Res. 2019 Jan;29(1):83-86
pubmed: 30514902
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Nat Commun. 2020 Apr 14;11(1):1833
pubmed: 32286255
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Autophagy. 2011 Jun;7(6):660-1
pubmed: 21460616
Cancer Res. 2018 Nov 15;78(22):6349-6353
pubmed: 30442814
Acta Pharmacol Sin. 2018 Apr;39(4):642-648
pubmed: 29239350
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Br J Cancer. 1999 Jan;79(1):59-64
pubmed: 10408694
Oxid Med Cell Longev. 2017;2017:4629495
pubmed: 29379583
Cancers (Basel). 2017 Nov 27;9(12):
pubmed: 29186827
PLoS One. 2013;8(1):e54969
pubmed: 23349993
Cancer Res. 1993 May 15;53(10 Suppl):2260-4
pubmed: 8485712
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
J Neurochem. 2021 May;157(4):1086-1101
pubmed: 32892352
Genome Med. 2020 Sep 28;12(1):83
pubmed: 32988398
Oncogene. 2016 Dec 8;35(49):6293-6308
pubmed: 27181208
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Mol Cell. 2018 Aug 16;71(4):606-620.e7
pubmed: 30118680
Biochem J. 2012 Feb 15;442(1):105-18
pubmed: 22115317
Oncotarget. 2016 Mar 29;7(13):16619-35
pubmed: 26918606
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Nature. 2018 Jan 4;553(7686):91-95
pubmed: 29160310
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373